Solid Tumors Clinical Trials

45 studies are recruiting for solid tumors in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Study of DS3610a in Participants With Advanced Solid Tumor

   This study is designed to assess the safety, tolerability, and efficacy of DS3610a, given as a single agent to participants with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin

   Locations

   4 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT07159126 on ClinicalTrials.gov

2. Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

   The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-u…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Arizona Cancer Center at UMC North ( Site 0018), Tucson, Arizona

   Locations

   782 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT03486873 on ClinicalTrials.gov

3. REC-7735 in Participants With Solid Tumors

   The study is designed to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of REC-7735 in participants with unresectable, locally advanced, or metastatic PIK3CA-H1047R mutated solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, Grand Rapids, Michigan

   Locations

   3 in total

   Run by

   Recursion Pharmaceuticals Inc.

   See if you can join NCT07819136 on ClinicalTrials.gov

4. 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

   Background: Blood, tissue, and tumor cells contain genes. Genes are made up of DNA. DNA is the "instruction book" for each cell. In some people with cancer, the genes that might have slowed the growth of their tumor were "turned off." Researchers want to see if a new drug can turn the genes back on…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03366116 on ClinicalTrials.gov

5. A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

   This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial w…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Emory University - Winship Cancer Institute, Atlanta, Georgia

   Locations

   58 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07492680 on ClinicalTrials.gov

6. A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

   A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   22 in total

   Run by

   Incyte Corporation

   See if you can join NCT07195916 on ClinicalTrials.gov

7. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

   The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Investigative Site US016, Anchorage, Alaska

   Locations

   229 in total

   Run by

   Incyte Corporation

   See if you can join NCT07522073 on ClinicalTrials.gov

8. A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

   This study is a first-in-human (FIH), Phase 1a/1b study of BG-C0902, a fully humanized anti-epidermal growth factor receptor (EGFR) and anti-mesenchymal-epithelial transition (MET) antibody, conjugated via an enzymatically cleavable linker to a topoisomerase 1 (TOPO1) inhibitor payload. The study a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas Md Anderson Cancer Center, Houston, Texas

   Locations

   14 in total

   Run by

   BeOne Medicines

   See if you can join NCT07181681 on ClinicalTrials.gov

9. A Study of GEN1106 in Participants With Solid Tumors

   The purpose of this trial is to learn about the safety and effectiveness of GEN1106 when it is used for the treatment of participants with certain types of cancer. The trial has multiple parts. The first part of the trial tests different doses of GEN1106 to find out if it is safe and determine what…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   10 in total

   Run by

   Genmab

   See if you can join NCT07416123 on ClinicalTrials.gov

10. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanc…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    42 in total

    Run by

    ORIC Pharmaceuticals

    See if you can join NCT05315700 on ClinicalTrials.gov

11. First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

    This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    7 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT06644755 on ClinicalTrials.gov

12. A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

    The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.

    Stage

    Phase 2

    Ages

    0 to 17

    Site

    University Hospitals Cleveland Medical Center, Cleveland, Ohio

    Locations

    5 in total

    Run by

    Spectrum Pharmaceuticals, Inc

    See if you can join NCT04570423 on ClinicalTrials.gov

13. A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

    The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Birmingham, Alabama

    Locations

    25 in total

    Run by

    Arcus Biosciences, Inc.

    See if you can join NCT05536141 on ClinicalTrials.gov

14. A Study of ZL-1310 in Participants With Selected Solid Tumors

    A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California San Francisco/Helen Diller Family Comprehensive Cancer Center, San Francisco, California

    Locations

    23 in total

    Run by

    Zai Lab (Shanghai) Co., Ltd.

    See if you can join NCT06885281 on ClinicalTrials.gov

15. A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

    This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorec…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Southern California Permanente Medical Group, Bellflower, California

    Locations

    100 in total

    Run by

    Mirati Therapeutics Inc.

    See if you can join NCT07415031 on ClinicalTrials.gov

16. Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI)

    This study evaluates whether optimization of ancillary therapies can improve the efficacy of immune checkpoint therapy in participants with solid tumors. The ancillary therapies being optimized include the avoidance of daily acetaminophen and cannabis/THC/CBD while prescribing aspirin and loratadin…

    Stage

    Phase 2

    Ages

    18 to 99

    Site

    University of Kentucky Markey Cancer Center, Lexington, Kentucky

    Run by

    Val Adams

    See if you can join NCT07661459 on ClinicalTrials.gov

17. A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

    This study is open to adults with different types of advanced cancer. People can take part if previous treatment was not successful, or no treatment exists. The purpose of this study is to find the highest dose of a medicine called BI 1703880 that people with advanced cancer can tolerate when taken…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Valkyrie Clinical Trials, Los Angeles, California

    Locations

    13 in total

    Run by

    Boehringer Ingelheim

    See if you can join NCT05471856 on ClinicalTrials.gov

18. Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

    A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USC Norris Comprehensive Cancer Center, Los Angeles, California

    Locations

    16 in total

    Run by

    Tyra Biosciences, Inc

    See if you can join NCT06915753 on ClinicalTrials.gov

19. A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

    The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors, including rare BRAF V600E…

    Stage

    Phase 2

    Ages

    8 and older

    Site

    Precision NextGen Oncology & Research Center, Beverly Hills, California

    Locations

    70 in total

    Run by

    Fore Biotherapeutics

    See if you can join NCT05503797 on ClinicalTrials.gov

20. A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

    To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Angeles Clinic and Research Institute, Los Angeles, California

    Locations

    39 in total

    Run by

    Incyte Corporation

    See if you can join NCT05836324 on ClinicalTrials.gov

21. Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

    The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Zai Lab Site 02003, Los Angeles, California

    Locations

    8 in total

    Run by

    Zai Lab (Shanghai) Co., Ltd.

    See if you can join NCT07374848 on ClinicalTrials.gov

22. A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

    This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic Hospital, Phoenix, Arizona

    Locations

    34 in total

    Run by

    Incyte Corporation

    See if you can join NCT06179160 on ClinicalTrials.gov

23. Study of AUBE00 in Patients With Solid Tumors

    This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and anti-tumor activity of AUBE00 in patients with locally advanced or metastatic solid tumors.The total numb…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan

    Locations

    4 in total

    Run by

    Chugai Pharmaceutical

    See if you can join NCT07030959 on ClinicalTrials.gov

24. Genomic Profiling in Cancer Patients

    The purpose of this study is to determine whether certain genes in cancer may be abnormal. When a gene is abnormal this is called a mutation. Most mutations in cancer cells are not inherited (passed down from parents) but happen after birth in the cancer itself. Most cancers have many mutations. So…

    Stage

    Not phased

    Ages

    Any age

    Site

    Norwalk Hospital, Norwalk, Connecticut

    Locations

    18 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT01775072 on ClinicalTrials.gov

25. Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors

    To study possible biomarkers that may be related to how SAR444881 works (either alone or when combined with cemiplimab) in participants with solid tumors.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Md Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06651593 on ClinicalTrials.gov